United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tr

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tr

United States - English - NLM (National Library of Medicine)

american health packaging - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 10 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in pa

United States - English - NLM (National Library of Medicine)

pai holdings, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 1100 mg in 5 ml - potassium citrate and citric acid oral solution usp is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting and tolerable, even when administered for l

United States - English - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate, sodium citrate and citric acid oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders. this product is highly concentrated and when administered after meals and before bedtime, allows one to maintain an alkaline urine ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosages. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion. severe renal impairment with ol

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - potassium citrate (unii: ee90oni6ff) (potassium cation - unii:295o53k152) - potassium citrate 1080 mg - potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (rta) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones. potassium citrate extended-release tablets are contraindicated in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown, or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). potassium citrate extended-release tablets are contraindicated in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esoph

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium cation 20 meq - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. 1.    for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2.    for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, eg, digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patie

United States - English - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate and citric acid oral solution usp is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting and tolerable, even when administered for l

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastroi

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets is contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. - in patients with peptic ulcer disease because of its ulcerogenic potential. - in patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). the ability of potassium citrate extended-release tablet to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. moreover, the rise in urinary ph resulting from potassium citrate extended-release tablet therapy might promote further bacterial growth. - in patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. animal reproduction studies have not been conducted. it is also not known whether potassium citrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. potassium citrate should be given to a pregnant woman only if clearly needed. the normal potassium ion content of human milk is about 13 meq/l. it is not known if potassium citrate has an effect on this content. potassium citrate should be given to a woman who is breast feeding only if clearly needed. safety and effectiveness in children have not been established.